Hylan G-F 20 Improves Hip Osteoarthritis: A Prospective, Randomized Study
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2020;8(14):18 Phys Sportsmed. 2010 Jun;38(2):35-47.What this means for my practice?
In general, intra-articular injections of hyaluronic acid (hylan G-F 20) and methylprednisolone acetate both provided improvements in overall health status, pain, and functional outcomes of patients with hip OA. Moreover, hylan G-F 20 was associated with significant improvements in outcomes within people with more advanced of symptomatic hip OA (KLG 3) for overall health status. A similar low frequency of adverse events occurred in both groups. Certain follow-up periods were not reported, as well as missing data for incidence of numbness for sub-groups of OA severity, which constituted limitations of the study.
Study Summary
Three-hundred and thirteen patients with symptomatic hip osteoarthritis (OA) were randomized into receiving intra-articular injections of hyaluronic acid (hylan G-F 20) or corticosteroid (methylprednisolone acetate [MPA]). The primary outcome of interest included pain measured by the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale. Secondary outcomes included the clinical observer global assessment (COGA), the patient global assessment (PGA), total WOMAC score, WOMAC A1 (pain while walking on a flat surface within 48 hours) score, the WOMAC stiffness subscale, and the WOMAC physical function subscale. All primary and secondary outcomes were measured at follow-up periods of 4, 8, 12, 16, 20, and 26 weeks; data was missing or not reported for several follow-up periods. Study results demonstrated that all primary and secondary outcomes significantly improved from baseline to week 26 for both treatment arms. COGA and PGA scores significantly improved using Hylan G-F 20 treatment in the Kellgren-Lawrence grade (KLG) 3 sub-group specifically. Therefore, hyaluronic acid (Hylan G-F 20) demonstrated significant benefits for improving overall health status of in patients with more severe OA.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
